Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.15720
Abstract: Key Points Question How does out-of-pocket spending on and the use of lenalidomide therapy differ between commercially insured patients enrolled in high-deductible health plans (HDHPs) and non-HDHPs? Findings In this cohort study of 3163 adults… read more here.
Keywords: use lenalidomide; lenalidomide therapy; commercially insured; spending use ... See more keywords
A concise review of lenalidomide therapy for follicular lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Orphan Drugs"
DOI: 10.1080/21678707.2017.1284659
Abstract: ABSTRACT Introduction: Lenalidomide, first introduced for the treatment of multiple myeloma in 2008, has been used in the treatment of various subtypes of non-Hodgkin lymphoma (NHL). Considering its mechanism of action, it has been associated… read more here.
Keywords: lymphoma; combination; review lenalidomide; lenalidomide therapy ... See more keywords
Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-117266
Abstract: Introduction: Myelodysplastic/Myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), previously known as RARS-T is now recognized as a full entity in the 2016 World Health Organization classification of myeloid neoplasms and acute leukemia. It is… read more here.
Keywords: thrombocytosis; disease; mds mpn; lenalidomide therapy ... See more keywords